REFERENCES
- Fournier B, Lagrange PH, Philippon A. β-lactamase gene promoters of 71 clinical strains of Klebsiella oxytoca. J Antimi-crob Chemother 1996; 40 (2): 460–463.
- Roberts JA, Webb SAR, Lipman J. Cefepime versus cef-tazidime: considerations for empirical use in critically ill patients. Int J Antimicrob Agents 2007; 29 (2): 117-128.
- Rousse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R. Ceftobiprole medocaril (BAL5788) treatment of exper-imental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn Microbiol Infec Dis 2006; 55 (4): 333–336.
- Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). In vitro activity of ceftobiprole against clinical isolates of Peu-domonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU study. J Antimicrob Chemother 2008; 62 (1): 206-208.
- Deresinski SC. Ceftobiprole: breaking therapeutic dogmas of the β-lactam class. Diagn Microbiol Infec Dis 2008; 61 (1): 82–85.
- Corvec S, Lepelletier D, Reynaud A, Dauvergne S, Gi-raudeau C, Caroff N. In vivo selection of an Escherichia coil iso-late highly resistant to ciprofloxacin and ceftazidime: role of a 4-bp duplication in acrR and ampC overexpression. Int J An-timicrob Agents 2008; 32 (2): 196–198.
- Queenan AM, Shang W, Kania M, Page MG, Bush K. In-teractions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007; 51 (9): 3089–3095.
- Högenauer C, Langner C, Beubler E, Lippe IT, Schicho R, Gorkiewicz G et al. Klebsiella oxytoca as a causative organ-ism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006; 355 (23): 2418-2426.